

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

August 18, 2022

Timothy P. Noyes Chief Executive Officer Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham, MA 02451

> Re: Aerovate Therapeutics, Inc. Registration Statement on Form S-3 Filed August 15, 2022 File No. 333-266883

Dear Mr. Noyes:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Alicia M. Tschirhart, Esq.